- Home
- NMRA vs RAPT Comparison
NMRA vs RAPT Comparison
Compare NMRA & RAPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMRA
- RAPT
- Stock Information
- Founded
- NMRA 2019
- RAPT 2015
- Country
- NMRA United States
- RAPT United States
- Employees
- NMRA N/A
- RAPT N/A
- Industry
- NMRA
- RAPT Biotechnology: Pharmaceutical Preparations
- Sector
- NMRA
- RAPT Health Care
- Exchange
- NMRA Nasdaq
- RAPT Nasdaq
- Market Cap
- NMRA 121.0M
- RAPT 122.9M
- IPO Year
- NMRA 2023
- RAPT 2019
- Fundamental
- Price
- NMRA $0.84
- RAPT $8.05
- Analyst Decision
- NMRA Buy
- RAPT Buy
- Analyst Count
- NMRA 8
- RAPT 5
- Target Price
- NMRA $9.29
- RAPT $42.00
- AVG Volume (30 Days)
- NMRA 1.4M
- RAPT 112.3K
- Earning Date
- NMRA 08-05-2025
- RAPT 08-07-2025
- Dividend Yield
- NMRA N/A
- RAPT N/A
- EPS Growth
- NMRA N/A
- RAPT N/A
- EPS
- NMRA N/A
- RAPT N/A
- Revenue
- NMRA N/A
- RAPT N/A
- Revenue This Year
- NMRA N/A
- RAPT N/A
- Revenue Next Year
- NMRA N/A
- RAPT N/A
- P/E Ratio
- NMRA N/A
- RAPT N/A
- Revenue Growth
- NMRA N/A
- RAPT N/A
- 52 Week Low
- NMRA $0.61
- RAPT $5.67
- 52 Week High
- NMRA $17.19
- RAPT $30.60
- Technical
- Relative Strength Index (RSI)
- NMRA 52.19
- RAPT 49.52
- Support Level
- NMRA $0.72
- RAPT $7.32
- Resistance Level
- NMRA $0.85
- RAPT $9.84
- Average True Range (ATR)
- NMRA 0.07
- RAPT 0.84
- MACD
- NMRA -0.01
- RAPT -0.09
- Stochastic Oscillator
- NMRA 62.35
- RAPT 39.53
About NMRA Neumora Therapeutics Inc.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.
About RAPT RAPT Therapeutics Inc.
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.